Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCCNASDAQ:IMNNNASDAQ:MEIPNASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCCIM Cannabis$1.55-15.7%$2.05$1.55▼$8.10$3.46M1.0390,430 shs8,720 shsIMNNImunon$1.02-6.4%$0.91$0.64▼$3.65$14.91M1.96891,853 shs79,323 shsMEIPMEI Pharma$2.34-0.4%$2.59$2.26▼$4.11$15.59M0.7645,513 shs9,920 shsSLGLSol-Gel Technologies$0.55-0.4%$0.65$0.33▼$1.65$15.27M1.29251,939 shs35,682 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCCIM Cannabis0.00%+3.95%-12.80%-20.69%-42.14%IMNNImunon0.00%+14.74%+22.38%+32.12%-33.54%MEIPMEI Pharma0.00%+2.17%-8.20%-4.08%-41.25%SLGLSol-Gel Technologies0.00%+2.61%-17.92%-50.89%-43.88%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMCCIM Cannabis1.3954 of 5 stars0.05.00.00.03.90.00.6IMNNImunon2.2174 of 5 stars3.72.00.00.02.30.01.3MEIPMEI Pharma4.1993 of 5 stars3.05.00.04.22.10.81.3SLGLSol-Gel Technologies2.3877 of 5 stars3.53.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCCIM Cannabis 0.00N/AN/AN/AIMNNImunon 3.33Buy$21.502,007.84% UpsideMEIPMEI Pharma 2.00Hold$7.00199.15% UpsideSLGLSol-Gel Technologies 3.00Buy$5.00812.41% UpsideCurrent Analyst Ratings BreakdownLatest IMCC, SLGL, MEIP, and IMNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025IMNNImunonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/24/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.002/27/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.002/19/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.001/24/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCCIM Cannabis$51.39M0.07N/AN/A$4.55 per share0.34IMNNImunon$500K29.83N/AN/A$1.42 per share0.72MEIPMEI Pharma$65.30M0.24$5.32 per share0.44$3.32 per share0.70SLGLSol-Gel Technologies$11.71M1.30N/AN/A$1.67 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCCIM Cannabis-$7.04M-$3.41N/AN/AN/A-25.55%-129.86%-23.63%3/31/2025 (Estimated)IMNNImunon-$19.51M-$1.60N/AN/AN/AN/A-230.05%-128.98%5/12/2025 (Estimated)MEIPMEI Pharma$17.78M-$5.73N/AN/AN/AN/A-84.92%-67.53%5/8/2025 (Estimated)SLGLSol-Gel Technologies-$27.24M-$0.34N/AN/AN/A-81.75%-27.17%-22.49%4/2/2025 (Estimated)Latest IMCC, SLGL, MEIP, and IMNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/2/2025N/ASLGLSol-Gel Technologies-$0.11N/AN/AN/A$2.00 millionN/A3/31/2025Q4 2024IMCCIM Cannabis-$0.39-$0.23+$0.16-$0.23$14.48 millionN/A2/12/2025Q2 2025MEIPMEI PharmaN/A-$0.48N/A-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCCIM CannabisN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCCIM Cannabis0.100.700.59IMNNImunonN/A2.302.30MEIPMEI PharmaN/A10.6610.66SLGLSol-Gel TechnologiesN/A5.815.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCCIM Cannabis7.68%IMNNImunon4.47%MEIPMEI Pharma52.38%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipIMCCIM Cannabis5.91%IMNNImunon5.00%MEIPMEI Pharma3.12%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCCIM Cannabis3402.23 million2.10 millionNot OptionableIMNNImunon3014.62 million13.78 millionNot OptionableMEIPMEI Pharma1006.66 million6.46 millionOptionableSLGLSol-Gel Technologies5027.86 million9.33 millionOptionableIMCC, SLGL, MEIP, and IMNN HeadlinesRecent News About These CompaniesSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Up 79.2% in MarchMarch 31 at 3:41 AM | americanbankingnews.comSLGL Gears Up to Report Q4 Earnings: Here's What You Should KnowFebruary 25, 2025 | zacks.comIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?February 7, 2025 | finance.yahoo.comSol Gel Technologies Ltd (SLGL) Stock Trading RecapDecember 26, 2024 | bovnews.comIs SolGel Technologies (SLGL) a Great Value Stock Right Now?December 25, 2024 | zacks.comSol-Gel Technologies Reports Strong Q3 2024 ResultsNovember 21, 2024 | markets.businessinsider.comSol-Gel announces 180-day extension to regain compliance with NasdaqNovember 21, 2024 | markets.businessinsider.comSolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should KnowNovember 20, 2024 | zacks.comSol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid RequirementNovember 20, 2024 | markets.businessinsider.comSol-Gel Technologies Third Quarter 2024 Earnings: Beats ExpectationsNovember 18, 2024 | finance.yahoo.comSol-Gel Technologies Ltd.: Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 15, 2024 | finanznachrichten.deSol-Gel Technologies reports Q3 EPS (1c) vs (23c) last yearNovember 15, 2024 | markets.businessinsider.comSol-Gel Technologies Reports Positive Q3 Financials and Strategic MovesNovember 15, 2024 | markets.businessinsider.comSol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue EstimatesNovember 15, 2024 | zacks.comSol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 15, 2024 | globenewswire.comsol gel technologies ltd - SLGLOctober 5, 2024 | foxbusiness.comSolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowSeptember 17, 2024 | zacks.comAll You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong BuyAugust 27, 2024 | zacks.comRaymond James Downgrades Sol-Gel Technologies (SLGL)August 20, 2024 | msn.comUPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesAugust 17, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMCC, SLGL, MEIP, and IMNN Company DescriptionsIM Cannabis NASDAQ:IMCC$1.55 -0.29 (-15.70%) As of 01:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.Imunon NASDAQ:IMNN$1.02 -0.07 (-6.42%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.MEI Pharma NASDAQ:MEIP$2.34 -0.01 (-0.43%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Sol-Gel Technologies NASDAQ:SLGL$0.55 0.00 (-0.36%) As of 01:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Netflix Poised for Significant Rally as a Safe Haven Stock Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Get Paid With Paychex: Dividends and Higher Prices Too Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
